OxyContin Files

Purdue Response to FDA, 2004

In a 2004 let­ter to the FDA, Purdue law­yers said the com­pany planned to con­tin­ue pro­mot­ing Oxy­Con­tin to doc­tors as a 12-hour drug for sev­er­al reas­ons, in­clud­ing “com­pet­it­ive ad­vant­age.”